US FDA’s ‘Platform’ Pathway Fits For LNPs And siRNA But Not Delivery Devices

 
• By Michael McCaughan

The US FDA’s new guidance defining a “Platform Technology Designation” makes clear that what counts as a “platform” may not match industry’s use of the term.

diving platform
Monoclonal antibody platforms also are among the technologies that could receive a platform designation from the FDA. • Source: Shutterstock

More from Review Pathways

More from Pathways & Standards